Arsenic suppresses cell survival via pirh2-mediated proteasomal degradation of ΔNp63 protein

Journal of Biological Chemistry

Volumn 288, Issue 5, 2013, Pages 2907-2913

  Yan, Wensheng ^a   Chen, Xiufang ^b   Zhang, Yanhong ^a   Zhang, Jin ^a   Jung, Yong Sam ^a   Chen, Xinbin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NANTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CELL SURVIVAL; DOSE-DEPENDENT MANNER; ECTOPIC EXPRESSIONS; FRONTLINE; GENE ENCODES; GROWTH SUPPRESSIONS; ISOFORMS; PROMYELOCYTIC LEUKEMIA; PROTEASOMAL DEGRADATION; SEQUENCE SIMILARITY; SQUAMOUS CELL CARCINOMA; THERAPEUTIC AGENTS; TUMOR CELLS; TUMOR SUPPRESSORS;

TRANSCRIPTION; TRANSCRIPTION FACTORS; TUMORS;

ARSENIC;

ARSENIC TRIOXIDE; PROTEASOME; PROTEIN P63; PROTEIN PIRH2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL DEATH; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY;

ARSENICALS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LEUPEPTINS; OXIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; PROTEOLYSIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84873297624     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.428607     Document Type: Article

References (53)

1. Harms, K., Nozell, S., and Chen, X. (2004) The common and distinct target genes of the p53 family transcription factors. Cell Mol. Life Sci. 61, 822-842
2. Westfall, M. D., Mays, D. J., Sniezek, J. C, and Pietenpol, J. A. (2003) The δ Np63 α phosphoprotein binds the p21 and 14-3-3 σ promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol. Cell. Biol. 23, 2264-2276
3. King, K. E., and Weinberg, W. C. (2007) p63: defining roles in morphogenesis, homeostasis, and neoplasia of the epidermis. Mol. Carcinog. 46, 716-724
4. Vanbokhoven, H., Melino, G., Candi, E., and Declercq, W. (2011) p63, a story of mice and men. J. Invest. Dermatol. 131, 1196-1207
5. Osada, M., Ohba, M., Kawahara, C, Ishioka, C, Kanamaru, R., Katoh, I., Ikawa, Y., Nimura, Y., Nakagawara, A., Obinata, M., and Ikawa, S. (1998) Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 4, 839-843
6. Trink, B., Okami, K., Wu, L., Sriuranpong, V., Jen, J., and Sidransky, D. (1998) A new human p53 homologue. Nat. Med. 4, 747-748
7. Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dötsch, V., Andrews, N. C, Caput, D., and McKeon, F. (1998) p63, ap53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2, 305-316
8. Dohn, M., Zhang, S., and Chen, X. (2001) p63α and δNp63α can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 20, 3193-3205
9. Flores, E. R., Sengupta, S., Miller, J. B., Newman, J. J., Bronson, R., Crowley, D., Yang, A., McKeon, F., and Jacks, T. (2005) Tumor predisposition in mice mutant for p63 and p73. Evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7, 363-373
10. Guo, X., Keyes, W. M., Papazoglu, C, Zuber, J., Li, W., Lowe, S. W., Vogel, H, and Mills, A. A. (2009) TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat. Cell Biol. 11, 1451-1457
11. Massion, P. P., Taflan, P. M., Jamshedur Rahman, S. M., Yildiz, P., Shyr, Y., Edgerton, M. E., Westfall, M. D., Roberts, J. R., Pietenpol, J. A., Carbone, D. P., and Gonzalez, A. L. (2003) Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 63, 7113-7121
12. Nonaka, D. (2012) A study of δNp63 expression in lung non-small cell carcinomas. Am. J. Surg. Pathol. 36, 895-899
13. Hibi, K., Trink, B., Patturajan, M., Westra, W. H., Caballero, O. L., Hill, D. E., Ratovitski, E. A., Jen, J., and Sidransky, D. (2000) AIS is an oncogene amplified in squamous cell carcinoma. Proc. Natl. Acad. Sci. U. S. A. 97, 5462-5467
14. Boldrup, L., Coates, P. J., Gu, X., and Nylander, K. (2007) ΔNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. J. Pathol. 213, 384-391
15. Mundt, H. M., Stremmel, W., Melino, G., Krammer, P. H., Schilling, T., and Müller, M. (2010) Dominant negative (δN) p63α induces drug resistance in hepatocellular carcinoma by interference with apoptosis signaling pathways. Biochem. Biophys. Res. Commun. 396, 335-341
16. Li, X., Chen, J., Yi, Y., Li, C, and Zhang, Y. (2012) DNA damage downregulates ΔNp63α and induces apoptosis independent of wild type p53. Biochem. Biophys. Res. Commun. 423, 338-343
17. Mitani, Y., Li, J., Weber, R. S., Lippman, S. L., Flores, E. R., Caulin, C, and El-Naggar, A. K. (2011) Expression and regulation of the δN and TAp63 isoforms in salivary gland tumorigenesis clinical and experimental findings. Am. J. Pathol. 179, 391-399
18. Zangen, R., Ratovitski, E., and Sidransky, D. (2005) δNp63α levels correlate with clinical tumor response to cisplatin. Cell Cycle 4, 1313-1315
19. Yan, W., and Chen, X. (2006) GPX2, a direct target of p63, inhibits oxidative stress-induced apoptosis in a p53-dependent manner. J. Biol. Chem. 281, 7856-7862
20. Yan, W., and Chen, X. (2007) Targeted repression of bone morphogenetic protein 7, a novel target of the p53 family, triggers proliferative defect in p53-deficient breast cancer cells. Cancer Res. 67, 9117-9124
21. Barbieri, C. E., Perez, C. A., Johnson, K. N, Ely, K. A., Billheimer, D., and Pietenpol, J. A. (2005) IGFBP-3 is a direct target of transcriptional regulation by δNp63α in squamous epithelium. Cancer Res. 65, 2314-2320
22. Hakem, A., Bohgaki, M., Lemmers, B., Tai, E., Salmena, L., Matysiak-Zablocki, E., Jung, Y. S., Karaskova, J., Kaustov, L., Duan, S., Madore, J., Boutros, P., Sheng, Y., Chesi, M., Bergsagel, P. L., Perez-Ordonez, B., Mes-Masson, A. M., Penn, L., Squire, J., Chen, X., Jurisica, I., Arrowsmith, C, Sanchez, O., Benchimol, S., and Hakem, R. (2011) Role of Pirh2 in mediating the regulation of p53 and c-Myc. PLoS Genet. 7, e1002360
23. Crook, T., Nicholls, J. M., Brooks, L., O'Nions, J., and Allday, M. J. (2000) High level expression of δN-p63, a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC) ? Oncogene 19, 3439-3444
24. Rocco, J. W., Leong, C. O., Kuperwasser, N., De Young, M. P., and Ellisen, L. W. (2006) p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9, 45-56
25. Emadi, A., and Gore, S. D. (2010) Arsenic trioxide, an old drug rediscovered. Blood Rev. 24, 191-199
26. Zhang, X. W., Yan, X. J., Zhou, Z. R., Yang, F. F., Wu, Z. Y., Sun, H. B., Liang, W. X., Song, A. X., Lallemand-Breitenbach, V., Jeanne, M., Zhang, Q. Y., Yang, H. Y., Huang, Q. H., Zhou, G. B., Tong, J. H., Zhang, Y., Wu, J. H., Hu, H. Y., De Thé, H., Chen, S. J., and Chen, Z. (2010) Arsenic trioxide controls the fate of the PML-RARa oncoprotein by directly binding PML. Science 328, 240-243
27. Jeanne, M., Lallemand-Breitenbach, V., Ferhi, O., Koken, M., Le Bras, M., Duffort, S., Peres, L., Berthier, C, Soilihi, H., Raught, B., and De Thé, H. (2010) PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 18, 88-98
28. Shackelford, D., Kenific, C, Blusztajn, A., Waxman, S., and Ren, R. (2006) Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. Cancer Res. 66, 11360-11369
29. Kim, J., Lee, J. J., Kim, J., Gardner, D., and Beachy, P. A. (2010) Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc. Natl. Acad. Sci. U. S. A. 107, 13432-13437
30. Mann, K. K., Colombo, M., and Miller, W. H., Jr. (2008) Arsenic trioxide decreases AKT protein in a caspase-dependent manner. Mol. Cancer Ther. 7, 1680-1687
31. Zhang, Q. Y., Mao, J. H., Liu, P., Huang, Q. H., Lu, J., Xie, Y. Y., Weng, L., Zhang, Y., Chen, Q., Chen, S. J., and Chen, Z. (2009) A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc. Natl. Acad. Sci. U. S. A. 106, 3378-3383
32. Yan, W., Zhang, Y., Zhang, J., Liu, S., Cho, S. J., and Chen, X. (2011) Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression. J. Biol. Chem. 286, 17478-17486
33. Jung, Y. S., Liu, G., and Chen, X. (2010) Pirh2 E3 ubiquitin ligase targets DNA polymerase 17 for 20 S proteasomal degradation. Mol. Cell. Biol. 30, 1041-1048
34. Debnath, J., Muthuswamy, S. K., and Brugge, J. S. (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30, 256-268
35. Carroll, D. K., Carroll, J. S., Leong, CO., Cheng, F., Brown, M., Mills, A. A., Brugge, J. S., and Ellisen, L. W. (2006) p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol. 8, 551-561
36. Zhang, J., Jun. Cho, S., and Chen, X. (2010) RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability. Proc. Natl. Acad. Sci. U. S. A. 107, 9614-9619
37. Shen, Y., Shen, Z. X., Yan, H., Chen, J., Zeng, X. Y., Li, J. M., Li, X. S., Wu, W., Xiong, S. M., Zhao, W. L., Tang, W., Wu, F., Liu, Y. F., Niu, C, Wang, Z. Y., Chen, S. J., and Chen, Z. (2001) Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. A comparison with conventional dosage. Leukemia 15, 735-741
38. Su, X., Chakravarti, D., Cho, M. S., Liu, L., Gi, Y. J., Lin, Y. L., Leung, M. L., El-Naggar, A., Creighton, C J., Suraokar, M. B., Wistuba, I., and Flores, E. R. (2010) TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 467, 986-990
39. Galli, F., Rossi, M., D'Alessandra, Y., De Simone, M., Lopardo, T., Haupt, Y., Alsheich-Bartok, O., Anzi, S., Shaulian, E., Calabrò, V., La Mantia, G., and Guerrini, L. (2010) MDM2 and Fbw7 cooperate to induce p63 protein degradation following DNA damage and cell differentiation. J. Cell Sci. 123, 2423-2433
40. Li, Y., Zhou, Z., and Chen, C. (2008) WWdomain-containing E3ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ. 15, 1941-1951
41. Rossi, M., Aqeilan, R. I., Neale, M., Candi, E., Salomoni, P., Knight, R. A., Croce, C. M., and Melino, G. (2006) The E3 ubiquitin ligase Itch controls the protein stabilityof p63. Proc. Natl. Acad. Sci. U. S. A. 103, 12753-12758
42. Rossi, M., De Simone, M., Pollice, A., Santoro, R., La Mantia, G., Guerrini, L., and Calabrò, V. (2006) Itch/AIP4 associates with and promotes p63 protein degradation. Cell Cycle 5, 1816-1822
43. Jung, Y. S., Qian, Y., Yan, W., and Chen, X. (2012) Pirh2 E3ubiquitin ligase modulates keratinocyte differentiation through p63. J. Invest. Dermatol., in press
44. Murata, K., Ota, S., Niki, T., Goto, A., Li, C. P., Ruriko, U. M., Ishikawa, S., Aburatani, H., Kuriyama, T., and Fukayama, M. (2007) p63. Key molecule in the early phase of epithelial abnormality in idiopathic pulmonary fibrosis. Exp. Mol. Pathol. 83, 367-376
45. Pelicano, H., Feng, L., Zhou, Y., Carew, J. S., Hileman, E. O., Plunkett, W., Keating, M. J., and Huang, P. (2003) Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem. 278, 37832-37839
46. Jing, Y., Dai, J., Chalmers-Redman, R. M., Tatton, W. G., and Waxman, S. (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94, 2102-2111
47. Choi, J. Y., Kim, B. M., Kim, Y. J., Woo, H. D., and Chung, H. W. (2007) Hypoxia/reoxygenation-induced cytotoxicity in cultured human lymphocytes. Biochem. Biophys. Res. Commun. 352, 366-371
48. Di Como, C. J., Urist, M. J., Babayan, I., Drobnjak, M., Hedvat, C. V., Teruya-Feldstein, J., Pohar, K., Hoos, A., and Cordon-Cardo, C. (2002) p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 8, 494-501
49. Wang, X. M., Yang, L. Y., Guo, L., Fan, C., and Wu, F. (2009) p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection. Cancer 115, 4554-4563
50. Logan, I. R., Gaughan, L., McCracken, S. R., Sapountzi, V., Leung, H. Y., and Robson, C. N. (2006) Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol. Cell. Biol. 26, 6502-6510
51. Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., Hakem, R., and Benchimol, S. (2003) Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112, 779-791
52. Jung, Y. S., Qian, Y., and Chen, X. (2011) The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation. J. Biol. Chem. 286, 35388-35395
53. Hattori, T., Isobe, T., Abe, K., Kikuchi, H., Kitagawa, K., Oda, T., Uchida, C., and Kitagawa, M. (2007) Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1. Cancer Res. 67, 10789-10795